Navigation Links
YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
Date:12/10/2009

ErbB-2, ERBB2), is associated with more aggressive breast cancers. Unwanted targeting of HER2 on cardiac myocytes (heart tissue) has been associated with damage to the heart in up to 28% of patients currently treated with trastuzumab when combined with certain chemotherapies (www.herceptin.com Full Prescribing Information).

Dr. Gregory P. Adams, Co-Leader, Molecular Medicine Program, Department of Medical Oncology, Fox Chase Cancer Center commented, "Antibodies with better selectivity for tumor tissue over normal tissues are an important goal for improved cancer therapy. They may offer improved efficacy over less selective antibodies on their own and their major advantage should lie in the precise delivery of toxic payloads to tumor cells, sparing toxicity to normal tissues."

The collaborative program is a multi-target, parallel-discovery research project funded by YM and NRC-BRI to develop YM's IntelliMab(TM) technology, a proprietary platform for generating new therapeutic antibodies that are designed to be as effective as, but safer than the current generation of antibodies. Collateral toxicity is an important challenge for numerous antibodies that indiscriminately target receptor in normal tissues as well as in the intended cancer cells. Furthermore, these antibodies are expected to be ideal candidates for delivering potent toxins to cancer cells. Depending on the cancer target selected, IntelliMab(TM) antibodies will be developed as naked antibodies and/or antibody conjugates. The YM team is led by Mr. Sean Thompson, Vice President of Strategic Projects and Corporate Development, who is collaborating with Dr. Maureen O'Connor, Leader of the NRC Genomics and Health Initiative Cancer Program.

"YM BioSciences has combined forces with the NRC-BRI, harnessing its world-class facility and considerable scientific expertise to create what we expect will be a suite of novel, high-val
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Biosciences Acquires Protein Forest
2. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
3. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
4. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
5. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
6. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
7. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
8. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
9. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
10. YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
11. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... announced today that it will release its full financial results ... on Thursday, March 12 th after market close, followed ... its financial results and business outlook. Participants should ... (412) 542-4135 (International) and request the InspireMD call. A live ...
(Date:3/6/2015)... , March 6, 2015 BioSpecifics Technologies ... developing first in class collagenase-based products marketed as XIAFLEX ... U.S. and XIAPEX ®  in the EU, announced today ... audio webcast at 8:30 a.m. ET on Friday, March ... year 2014 financial results and provide a corporate update. ...
(Date:3/6/2015)... 2015 Die ... der Assistance Publique - Hôpitaux de ... eine französische, gemeinschaftliche, randomisierte Kontrollstudie für die ... Verglichen werden Patienten mit fortgeschrittenem hepatozellulärem Karzinom ... Sorafenib behandelt wurden. Die Ergebnisse werden für ...
(Date:3/5/2015)... St. Paul, Minn. (PRWEB) March 05, 2015 ... meet in Pasadena this summer at the Annual Meeting ... program are starting to be released online now at ... just been announced for the meeting, to be held ... includes newly announced Special Sessions, Field Trips, Workshops, and ...
Breaking Biology Technology:InspireMD to Report Financial Results for the Fourth Quarter and Year Ended December 31, 2014 on Thursday, March 12th 2BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6American Phytopathological Society Announces Annual Meeting Daily Schedule 2
... Feb. 12 Pharmacyclics, Inc.,(Nasdaq: PCYC ), ... clinical testing and several late stage preclinical programs,announced today ... new board,member. , Robert W. ... CEO of the,company after acting as interim CEO for ...
... Company Exceeds Sales and Earnings GuidanceCompany Reiterates 2009 Earnings ... 12 Cephalon, Inc . (Nasdaq: ... $1.943 billion, compared to sales of $1.727 billion for ... income per common share for the full year 2008 ...
... Inc., announced,today the appointment of John P. Walker as ... of Directors. Walker was most recently the,Chairman and ... in January 2009. , (Photo: ... Bio is focused on the development of induced pluripotent ...
Cached Biology Technology:Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 2Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 3Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 4Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 5Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 6Cephalon's New Product Launches Pace Record 2008 Sales 2Cephalon's New Product Launches Pace Record 2008 Sales 3Cephalon's New Product Launches Pace Record 2008 Sales 4Cephalon's New Product Launches Pace Record 2008 Sales 5Cephalon's New Product Launches Pace Record 2008 Sales 6Cephalon's New Product Launches Pace Record 2008 Sales 7Cephalon's New Product Launches Pace Record 2008 Sales 8Cephalon's New Product Launches Pace Record 2008 Sales 9Cephalon's New Product Launches Pace Record 2008 Sales 10Cephalon's New Product Launches Pace Record 2008 Sales 11Cephalon's New Product Launches Pace Record 2008 Sales 12Cephalon's New Product Launches Pace Record 2008 Sales 13Cephalon's New Product Launches Pace Record 2008 Sales 14Cephalon's New Product Launches Pace Record 2008 Sales 15Cephalon's New Product Launches Pace Record 2008 Sales 16Cephalon's New Product Launches Pace Record 2008 Sales 17Cephalon's New Product Launches Pace Record 2008 Sales 18Cephalon's New Product Launches Pace Record 2008 Sales 19Cephalon's New Product Launches Pace Record 2008 Sales 20Cephalon's New Product Launches Pace Record 2008 Sales 21iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer 2
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... Aug. 5, 2013 - For a new study in ... how different concentrations of lipids affect growth performance in ... of lipids affect pigs. According to the researchers, ... absorption because swine genetics have improved over the years. ...
... University of Illinois scientists have evidence that lifelong exposure ... colon cancer by repressing a signal that leads to accelerated ... our study, we report a change in the expression of ... Chen, a U of I professor of food science and ...
... interact with one anotherand not just today. Scientists are studying ... the world in the ancient past and to identify ways ... to a new study published in the August 2 issue ... throughout Earth,s history, but the recent rate of global warming ...
Cached Biology News:Researchers re-evaluate swine nutrition 2Scientists learn how soy foods protect against colon cancer 2Looking to the past to predict the future of climate change 2
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... recombinant human protein produced in E. coli and ... A type enzymes. The mode of inhibition ... a 1:1 ratio. The enzyme has been shown ... cell types. Addition of the ribonuclease inhibitor has ...
Biology Products: